Circulating Tumor DNA: A Promising Tool for Monitoring and Guiding Colorectal Cancer Treatment

Circulating tumor DNA (ctDNA) testing holds significant potential to improve outcomes for colorectal cancer patients by enabling early detection of minimal residual disease, guiding adjuvant therapy decisions, and monitoring treatment response.